FibroBiologics今日宣告,其一项针对椎间盘退行性疾病治疗的新美国专利已正式获批。此项专利聚焦于成纤维细胞条件培养基的应用,为该疾病的治疗开辟了全新路径。这标志着公司在再生医学领域的持续深耕又迈出了坚实一步。
FibroBiologics今日宣告,其一项针对椎间盘退行性疾病治疗的新美国专利已正式获批。此项专利聚焦于成纤维细胞条件培养基的应用,为该疾病的治疗开辟了全新路径。这标志着公司在再生医学领域的持续深耕又迈出了坚实一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.